hgsoc

UNC0379 is a selective, substrate-competitive inhibitor of the lysine methyltransferase (SETD8).

Datopotamab deruxtecan (DS-1062) is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) with antitumor activity. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.

ALDH1A1-IN-5 (compound 25) is a potent inhibitor of aldehyde dehydrogenase 1A1 (ALDH1A1), exhibiting EC50 values of 83 µM, 45 µM, and 43 µM for ALDH1A1, ALDH1A2, and ALDH1A3, respectively. This compound holds potential for research in high-grade serous ovarian cancer (HGSOC).

PHY34 is a late stage autophagy inhibitor with nanomolar level inhibitory effect and anti-tumor activity against high-grade serous ovarian cancer (HGSOC) in vivo.

Datopotamab (CDP7657) is a TROP2-targeting antibody that is a naked antibody to Datopotamab deruxtecan and can be used to synthesize active antibody conjugators (Datopotamab deruxtecan).

ReACp53 is a cell-penetrating peptide, designed to inhibit p53 amyloid formation, resues p53 function in cancer cell lines and in organoids derived from high-grade serous ovarian carcinomas (HGSOC).